Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Imaging CAR T cell therapy with PSMA-targeted positron emission tomography.

Minn I, Huss DJ, Ahn HH, Chinn TM, Park A, Jones J, Brummet M, Rowe SP, Sysa-Shah P, Du Y, Levitsky HI, Pomper MG.

Sci Adv. 2019 Jul 3;5(7):eaaw5096. doi: 10.1126/sciadv.aaw5096. eCollection 2019 Jul.

2.

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.

Hoves S, Ooi CH, Wolter C, Sade H, Bissinger S, Schmittnaegel M, Ast O, Giusti AM, Wartha K, Runza V, Xu W, Kienast Y, Cannarile MA, Levitsky H, Romagnoli S, De Palma M, Rüttinger D, Ries CH.

J Exp Med. 2018 Mar 5;215(3):859-876. doi: 10.1084/jem.20171440. Epub 2018 Feb 7.

3.

A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.

Walters JN, Ferraro B, Duperret EK, Kraynyak KA, Chu J, Saint-Fleur A, Yan J, Levitsky H, Khan AS, Sardesai NY, Weiner DB.

Mol Ther. 2017 Apr 5;25(4):976-988. doi: 10.1016/j.ymthe.2017.01.022. Epub 2017 Feb 22.

4.

De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.

Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P.

Cancer Immunol Res. 2016 Apr;4(4):279-88. doi: 10.1158/2326-6066.CIR-16-0045. Review.

5.

Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging.

Kadayakkara DK, Korrer MJ, Bulte JW, Levitsky HI.

Cancer Res. 2015 Jan 1;75(1):51-61. doi: 10.1158/0008-5472.CAN-14-0820. Epub 2014 Nov 11.

6.

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Rüttinger D.

Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2.

7.

Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.

Fu J, Malm IJ, Kadayakkara DK, Levitsky H, Pardoll D, Kim YJ.

Cancer Res. 2014 Aug 1;74(15):4042-52. doi: 10.1158/0008-5472.CAN-13-2685. Epub 2014 May 8.

8.

Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.

Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, Strickland SA, Jagasia M, Savani BN, Fraser JW, Sadrzadeh H, Rajkhowa T, Ito S, Jain NA, Battiwalla M, Fathi AT, Levis MJ, Barrett AJ, Hourigan CS.

Leukemia. 2014 May;28(5):1167-70. doi: 10.1038/leu.2014.14. Epub 2014 Jan 10. No abstract available.

9.

TE-array--a high throughput tool to study transposon transcription.

Gnanakkan VP, Jaffe AE, Dai L, Fu J, Wheelan SJ, Levitsky HI, Boeke JD, Burns KH.

BMC Genomics. 2013 Dec 10;14:869. doi: 10.1186/1471-2164-14-869.

10.

Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.

Qin L, Smith BD, Tsai HL, Yaghi NK, Neela PH, Moake M, Fu J, Kasamon YL, Prince GT, Goswami M, Rosner GL, Levitsky HI, Hourigan CS.

Blood Cancer J. 2013 Sep 6;3:e145. doi: 10.1038/bcj.2013.44.

11.

RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.

Yin X, Luistro L, Zhong H, Smith M, Nevins T, Schostack K, Hilton H, Lin TA, Truitt T, Biondi D, Wang X, Packman K, Rosinski J, Berkofsky-Fessler W, Tang JP, Pant S, Geho D, Vega-Harring S, Demario M, Levitsky H, Simcox M.

Clin Cancer Res. 2013 Oct 15;19(20):5686-98. doi: 10.1158/1078-0432.CCR-13-0405. Epub 2013 Aug 23.

12.
13.

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.

Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J, Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V, Levy R.

J Clin Invest. 2013 Jun;123(6):2447-63. Erratum in: J Clin Invest. 2013 Nov;123(11):4980.

14.

T cell assays and MIATA: the essential minimum for maximum impact.

Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM.

Immunity. 2012 Jul 27;37(1):1-2. doi: 10.1016/j.immuni.2012.07.010. No abstract available.

15.

Towards curative cancer immunotherapy: overcoming posttherapy tumor escape.

Zhou G, Levitsky H.

Clin Dev Immunol. 2012;2012:124187. doi: 10.1155/2012/124187. Epub 2012 May 31. Review.

16.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

17.

Evaluation of current cancer immunotherapy: hemato-oncology.

Hourigan CS, Levitsky HI.

Cancer J. 2011 Sep-Oct;17(5):309-24. doi: 10.1097/PPO.0b013e3182341fde. Review.

18.

High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas.

Gladstone DE, Bolaños-Meade J, Huff CA, Zahurak M, Flinn I, Borrello I, Luznik L, Fuchs E, Kasamon Y, Matsui W, Powell J, Levitsky H, Brodsky RA, Ambinder R, Jones RJ, Swinnen LJ.

Leuk Lymphoma. 2011 Nov;52(11):2076-81. doi: 10.3109/10428194.2011.594191. Epub 2011 Jul 14.

19.

Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response.

Zhou G, Ding ZC, Fu J, Levitsky HI.

J Immunol. 2011 Feb 15;186(4):2148-55. doi: 10.4049/jimmunol.1002917. Epub 2011 Jan 17.

20.

Characterization of chronic myeloid leukemia stem cells.

Gerber JM, Qin L, Kowalski J, Smith BD, Griffin CA, Vala MS, Collector MI, Perkins B, Zahurak M, Matsui W, Gocke CD, Sharkis SJ, Levitsky HI, Jones RJ.

Am J Hematol. 2011 Jan;86(1):31-7. doi: 10.1002/ajh.21915.

21.

Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.

Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM.

Cancer Immunol Immunother. 2011 Jan;60(1):15-22. doi: 10.1007/s00262-010-0940-z. Epub 2010 Nov 16.

22.

Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.

Kanakry CG, Hess AD, Gocke CD, Thoburn C, Kos F, Meyer C, Briel J, Luznik L, Smith BD, Levitsky H, Karp JE.

Blood. 2011 Jan 13;117(2):608-17. doi: 10.1182/blood-2010-04-277939. Epub 2010 Oct 8.

23.

High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Luznik L, Bolaños-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, Huff CA, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ.

Blood. 2010 Apr 22;115(16):3224-30. doi: 10.1182/blood-2009-11-251595. Epub 2010 Feb 2.

24.

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.

Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI.

Clin Cancer Res. 2010 Jan 1;16(1):338-47. doi: 10.1158/1078-0432.CCR-09-2046.

25.

"MIATA"-minimal information about T cell assays.

Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM.

Immunity. 2009 Oct 16;31(4):527-8. doi: 10.1016/j.immuni.2009.09.007.

26.

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).

Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, Alyea EP, Stone RM, Damon LE, Linker CA, Maslyar DJ, Hege KM.

Blood. 2009 Aug 27;114(9):1736-45. doi: 10.1182/blood-2009-02-205278. Epub 2009 Jun 25.

27.

Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand.

Bohana-Kashtan O, Morisot S, Hildreth R, Brayton C, Levitsky HI, Civin CI.

J Immunol. 2009 Jul 1;183(1):696-705. doi: 10.4049/jimmunol.0800561. Epub 2009 Jun 17.

28.

Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes.

Long CM, van Laarhoven HW, Bulte JW, Levitsky HI.

Cancer Res. 2009 Apr 1;69(7):3180-7. doi: 10.1158/0008-5472.CAN-08-3691. Epub 2009 Mar 10.

29.

Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer.

Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, Overwijk WW, Cooper LJ, Gelovani J, Hwu P.

Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14342-6. doi: 10.1073/pnas.0804105105. Epub 2008 Sep 15.

30.

The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells.

Symons HJ, Levy MY, Wang J, Zhou X, Zhou G, Cohen SE, Luznik L, Levitsky HI, Fuchs EJ.

Biol Blood Marrow Transplant. 2008 May;14(5):499-509. doi: 10.1016/j.bbmt.2008.02.013.

31.

Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments.

Stebbing J, Wood C, Atkins M, Bukowski R, Litwin S, Bower M, Parsa A, Levitsky H.

Cancer. 2008 Mar 1;112(5):955-61. doi: 10.1002/cncr.23273.

32.

Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation.

Mirmonsef P, Tan G, Zhou G, Morino T, Noonan K, Borrello I, Levitsky HI.

Blood. 2008 Feb 15;111(4):2112-21. Epub 2007 Dec 6.

33.

Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).

Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A.

Vaccine. 2007 Sep 27;25 Suppl 2:B97-B109. Review.

PMID:
17916465
34.

Magnetoelectroporation: improved labeling of neural stem cells and leukocytes for cellular magnetic resonance imaging using a single FDA-approved agent.

Walczak P, Ruiz-Cabello J, Kedziorek DA, Gilad AA, Lin S, Barnett B, Qin L, Levitsky H, Bulte JW.

Nanomedicine. 2006 Jun;2(2):89-94.

PMID:
17292120
36.

Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice.

Hung CF, Tsai YC, He L, Coukos G, Fodor I, Qin L, Levitsky H, Wu TC.

Gene Ther. 2007 Jan;14(1):20-9. Epub 2006 Aug 17.

PMID:
16915291
37.

In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.

Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, Levitsky H, Sotomayor EM.

Blood. 2006 Apr 1;107(7):2871-8. Epub 2005 Dec 8.

38.

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.

Zhou G, Drake CG, Levitsky HI.

Blood. 2006 Jan 15;107(2):628-36. Epub 2005 Sep 22.

39.

Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors.

Noonan K, Matsui W, Serafini P, Carbley R, Tan G, Khalili J, Bonyhadi M, Levitsky H, Whartenby K, Borrello I.

Cancer Res. 2005 Mar 1;65(5):2026-34.

40.

Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression.

Zhou G, Lu Z, McCadden JD, Levitsky HI, Marson AL.

J Exp Med. 2004 Dec 20;200(12):1581-92. Epub 2004 Dec 13.

41.

Role of LAG-3 in regulatory T cells.

Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DA.

Immunity. 2004 Oct;21(4):503-13.

42.

Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy.

Kast WM, Levitsky H, Marincola FM.

J Transl Med. 2004 Jun 22;2(1):20.

43.

Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.

Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, Bien H, Borrello IM, Levitsky HI, Sotomayor EM.

Cancer Res. 2003 Dec 15;63(24):9007-15.

44.

Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells.

Cui Y, Kelleher E, Straley E, Fuchs E, Gorski K, Levitsky H, Borrello I, Civin CI, Schoenberger SP, Cheng L, Pardoll DM, Whartenby KA.

Nat Med. 2003 Jul;9(7):952-8.

PMID:
12778137
45.

Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.

Luznik L, Slansky JE, Jalla S, Borrello I, Levitsky HI, Pardoll DM, Fuchs EJ.

Blood. 2003 Feb 15;101(4):1645-52. Epub 2002 Oct 24.

PMID:
12406877
46.

Tumor-specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines.

Housseau F, Langer DA, Oberholtzer SD, Moorthy A, Levitsky HI, Pardoll DM, Topalian SL.

Int J Cancer. 2002 Mar 1;98(1):57-62.

47.

New Developments in the Therapy of Acute Myelocytic Leukemia.

Gorin NC, Estey E, Jones RJ, Levitsky HI, Borrello I, Slavin S.

Hematology Am Soc Hematol Educ Program. 2000:69-89.

PMID:
11701536
48.

Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression.

Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O'Carroll K, Levitsky HI.

Blood. 2001 Aug 15;98(4):1070-7.

PMID:
11493453
49.

Specific immunotherapy by genetically engineered APCs: the "guided missile" strategy.

Wu B, Wu JM, Miagkov A, Adams RN, Levitsky HI, Drachman DB.

J Immunol. 2001 Apr 1;166(7):4773-9.

50.

When magic bullets miss their mark.

Levitsky HI.

Blood. 2001 Feb 15;97(4):833. No abstract available.

PMID:
11159502

Supplemental Content

Loading ...
Support Center